White Paper

Fighting Cancer: How Biomarker Testing and 3 Key Research Tools Shape Immunotherapy Drug Development

Planning and Implementing Biomarker Testing for Immuno-Oncology Trials

With the field of immuno-oncology constantly changing as a result of advances in cancer biology and immunology research, an understanding of clinical biomarker testing is needed now more than ever.

In this complimentary white paper, learn about the importance of diverse clinical biomarker testing and the challenges diverse clinical biomarker requirements face in in these trials.

Also in this white paper, learn how Q2 Solutions brings 3 key research tools - anatomic pathology, flow cytometry, and genomics - into immuno-oncology clinical trials to drive successful studies for biopharma sponsors.

Contact us to learn how we can advance your immuno-oncology drug development program.


More Resources

The Pivotal Roles Genomics and Flow Cytometry Play in Immuno-oncology Clinical Development
3 Tools You Should Be Using Now to Improve Oncology Care through Minimal Residual Disease Testing
6 Key Elements of Successful Companion Diagnostic Development
View All